Logo image of BAYN.DE

BAYER AG-REG (BAYN.DE) Stock Fundamental Analysis

FRA:BAYN - Deutsche Boerse Ag - DE000BAY0017 - Common Stock - Currency: EUR

22.77  +0.1 (+0.44%)

Fundamental Rating

2

BAYN gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 49 industry peers in the Pharmaceuticals industry. BAYN has a bad profitability rating. Also its financial health evaluation is rather negative. BAYN is cheap, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

BAYN had positive earnings in the past year.
In the past year BAYN had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: BAYN reported negative net income in multiple years.
Of the past 5 years BAYN 4 years had a positive operating cash flow.
BAYN.DE Yearly Net Income VS EBIT VS OCF VS FCFBAYN.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5B -5B -10B

1.2 Ratios

With a Return On Assets value of -0.82%, BAYN is not doing good in the industry: 61.22% of the companies in the same industry are doing better.
BAYN has a worse Return On Equity (-2.88%) than 61.22% of its industry peers.
BAYN's Return On Invested Capital of 1.71% is on the low side compared to the rest of the industry. BAYN is outperformed by 63.27% of its industry peers.
BAYN had an Average Return On Invested Capital over the past 3 years of 6.14%. This is significantly below the industry average of 13.18%.
The last Return On Invested Capital (1.71%) for BAYN is well below the 3 year average (6.14%), which needs to be investigated, but indicates that BAYN had better years and this may not be a problem.
Industry RankSector Rank
ROA -0.82%
ROE -2.88%
ROIC 1.71%
ROA(3y)0.54%
ROA(5y)-0.82%
ROE(3y)1.6%
ROE(5y)-4.19%
ROIC(3y)6.14%
ROIC(5y)N/A
BAYN.DE Yearly ROA, ROE, ROICBAYN.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10 -10 -20 -30

1.3 Margins

BAYN has a worse Operating Margin (4.24%) than 61.22% of its industry peers.
With a Gross Margin value of 57.14%, BAYN is not doing good in the industry: 71.43% of the companies in the same industry are doing better.
BAYN's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 4.24%
PM (TTM) N/A
GM 57.14%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.87%
GM growth 5Y0.14%
BAYN.DE Yearly Profit, Operating, Gross MarginsBAYN.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40 60

More info and screens

1

2. Health

2.1 Basic Checks

BAYN has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
There is no outstanding debt for BAYN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BAYN.DE Yearly Shares OutstandingBAYN.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M
BAYN.DE Yearly Total Debt VS Total AssetsBAYN.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20B 40B 60B 80B 100B

2.2 Solvency

Based on the Altman-Z score of 0.89, we must say that BAYN is in the distress zone and has some risk of bankruptcy.
BAYN's Altman-Z score of 0.89 is in line compared to the rest of the industry. BAYN outperforms 40.82% of its industry peers.
BAYN has a debt to FCF ratio of 7.76. This is a slightly negative value and a sign of low solvency as BAYN would need 7.76 years to pay back of all of its debts.
BAYN's Debt to FCF ratio of 7.76 is on the low side compared to the rest of the industry. BAYN is outperformed by 61.22% of its industry peers.
A Debt/Equity ratio of 1.20 is on the high side and indicates that BAYN has dependencies on debt financing.
BAYN has a worse Debt to Equity ratio (1.20) than 67.35% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.2
Debt/FCF 7.76
Altman-Z 0.89
ROIC/WACC0.34
WACC5.03%
BAYN.DE Yearly LT Debt VS Equity VS FCFBAYN.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 10B 20B 30B 40B

2.3 Liquidity

A Current Ratio of 1.32 indicates that BAYN should not have too much problems paying its short term obligations.
BAYN's Current ratio of 1.32 is on the low side compared to the rest of the industry. BAYN is outperformed by 65.31% of its industry peers.
BAYN has a Quick Ratio of 1.32. This is a bad value and indicates that BAYN is not financially healthy enough and could expect problems in meeting its short term obligations.
BAYN has a worse Quick ratio (0.81) than 69.39% of its industry peers.
Industry RankSector Rank
Current Ratio 1.32
Quick Ratio 0.81
BAYN.DE Yearly Current Assets VS Current LiabilitesBAYN.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10B 20B 30B

More info and screens

2

3. Growth

3.1 Past

The earnings per share for BAYN have decreased strongly by -21.09% in the last year.
Measured over the past years, BAYN shows a decrease in Earnings Per Share. The EPS has been decreasing by -5.27% on average per year.
EPS 1Y (TTM)-21.09%
EPS 3Y-8.12%
EPS 5Y-5.27%
EPS Q2Q%-43.24%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-1.12%

3.2 Future

The Earnings Per Share is expected to grow by 2.36% on average over the next years.
BAYN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.07% yearly.
EPS Next Y-6.73%
EPS Next 2Y0.2%
EPS Next 3Y0.5%
EPS Next 5Y2.36%
Revenue Next Year0.12%
Revenue Next 2Y0.98%
Revenue Next 3Y1.38%
Revenue Next 5Y1.07%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BAYN.DE Yearly Revenue VS EstimatesBAYN.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 10B 20B 30B 40B 50B
BAYN.DE Yearly EPS VS EstimatesBAYN.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2 4 6

More info and screens

7

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 4.51, the valuation of BAYN can be described as very cheap.
Compared to the rest of the industry, the Price/Earnings ratio of BAYN indicates a rather cheap valuation: BAYN is cheaper than 93.88% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 28.80, BAYN is valued rather cheaply.
A Price/Forward Earnings ratio of 4.83 indicates a rather cheap valuation of BAYN.
Based on the Price/Forward Earnings ratio, BAYN is valued cheaper than 95.92% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 21.91. BAYN is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 4.51
Fwd PE 4.83
BAYN.DE Price Earnings VS Forward Price EarningsBAYN.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

BAYN's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BAYN is cheaper than 89.80% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, BAYN is valued cheaply inside the industry as 97.96% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 4.22
EV/EBITDA 5.86
BAYN.DE Per share dataBAYN.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.2%
EPS Next 3Y0.5%

More info and screens

1

5. Dividend

5.1 Amount

With a yearly dividend of 0.48%, BAYN is not a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 2.90, BAYN has a dividend in line with its industry peers.
Compared to an average S&P500 Dividend Yield of 2.39, BAYN's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.48%

5.2 History

The dividend of BAYN decreases each year by -2.26%.
Dividend Growth(5Y)-2.26%
Div Incr Years1
Div Non Decr Years3
BAYN.DE Yearly Dividends per shareBAYN.DE Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 0.5 1 1.5 2 2.5

5.3 Sustainability

The earnings of BAYN are negative and hence is the payout ratio. BAYN will probably not be able to sustain this dividend level.
DP-15.11%
EPS Next 2Y0.2%
EPS Next 3Y0.5%
BAYN.DE Yearly Income VS Free CF VS DividendBAYN.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5B -5B -10B

More info and screens

BAYER AG-REG

FRA:BAYN (3/28/2025, 1:32:06 PM)

22.77

+0.1 (+0.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-05 2025-03-05/bmo
Earnings (Next)05-13 2025-05-13
Inst Owners47.61%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap22.37B
Analysts67.14
Price Target27.68 (21.56%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.48%
Yearly Dividend2.42
Dividend Growth(5Y)-2.26%
DP-15.11%
Div Incr Years1
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.42%
Min EPS beat(2)-17.26%
Max EPS beat(2)4.42%
EPS beat(4)3
Avg EPS beat(4)5.73%
Min EPS beat(4)-17.26%
Max EPS beat(4)23.22%
EPS beat(8)5
Avg EPS beat(8)-3.43%
EPS beat(12)8
Avg EPS beat(12)0.38%
EPS beat(16)12
Avg EPS beat(16)2.03%
Revenue beat(2)1
Avg Revenue beat(2)-1.68%
Min Revenue beat(2)-3.42%
Max Revenue beat(2)0.05%
Revenue beat(4)1
Avg Revenue beat(4)-2.33%
Min Revenue beat(4)-4%
Max Revenue beat(4)0.05%
Revenue beat(8)1
Avg Revenue beat(8)-3.48%
Revenue beat(12)5
Avg Revenue beat(12)-1.54%
Revenue beat(16)8
Avg Revenue beat(16)-0.91%
PT rev (1m)0%
PT rev (3m)-1.16%
EPS NQ rev (1m)-0.8%
EPS NQ rev (3m)-0.47%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.15%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.08%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.28%
Valuation
Industry RankSector Rank
PE 4.51
Fwd PE 4.83
P/S 0.48
P/FCF 4.22
P/OCF 2.8
P/B 0.73
P/tB N/A
EV/EBITDA 5.86
EPS(TTM)5.05
EY22.18%
EPS(NY)4.71
Fwd EY20.69%
FCF(TTM)5.4
FCFY23.71%
OCF(TTM)8.12
OCFY35.67%
SpS47.58
BVpS31.11
TBVpS-20.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -0.82%
ROE -2.88%
ROCE 2.42%
ROIC 1.71%
ROICexc 1.85%
ROICexgc 5.52%
OM 4.24%
PM (TTM) N/A
GM 57.14%
FCFM 11.35%
ROA(3y)0.54%
ROA(5y)-0.82%
ROE(3y)1.6%
ROE(5y)-4.19%
ROIC(3y)6.14%
ROIC(5y)N/A
ROICexc(3y)6.89%
ROICexc(5y)N/A
ROICexgc(3y)31.11%
ROICexgc(5y)N/A
ROCE(3y)8.72%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.87%
GM growth 5Y0.14%
F-Score6
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity 1.2
Debt/FCF 7.76
Debt/EBITDA 3.88
Cap/Depr 35.8%
Cap/Sales 5.72%
Interest Coverage 1.07
Cash Conversion 84.37%
Profit Quality N/A
Current Ratio 1.32
Quick Ratio 0.81
Altman-Z 0.89
F-Score6
WACC5.03%
ROIC/WACC0.34
Cap/Depr(3y)52.75%
Cap/Depr(5y)45.17%
Cap/Sales(3y)5.84%
Cap/Sales(5y)5.89%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-21.09%
EPS 3Y-8.12%
EPS 5Y-5.27%
EPS Q2Q%-43.24%
EPS Next Y-6.73%
EPS Next 2Y0.2%
EPS Next 3Y0.5%
EPS Next 5Y2.36%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-1.12%
Revenue Next Year0.12%
Revenue Next 2Y0.98%
Revenue Next 3Y1.38%
Revenue Next 5Y1.07%
EBIT growth 1Y1468.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year28.33%
EBIT Next 3Y8.68%
EBIT Next 5Y4.13%
FCF growth 1Y23.15%
FCF growth 3Y-1.53%
FCF growth 5Y-14.98%
OCF growth 1Y12.83%
OCF growth 3Y1.48%
OCF growth 5Y-8.36%